

COMPANY ANNOUNCEMENT

Valby, Denmark, 28 September, 2026

Lars Bang, Executive Vice President, Product Development & Supply, has passed away

Valby, Denmark, 28 September, 2026 – H. Lundbeck A/S (Lundbeck)

It is with profound sadness that we share that Lars Bang, Executive Vice President, Product Development & Supply, has passed away.

Lars joined Lundbeck in 1988 and dedicated almost four decades of his professional life to the company. During that time, he held a number of senior leadership positions across Lundbeck spanning R&D, corporate strategy, international sales and marketing, and production and supply. From 2003, Lars held senior leadership responsibility for our production and supply organization, most recently as Executive Vice President, Product Development & Supply. Lars was a member of Lundbeck's Executive Leadership Team and Registered Executive Management.

"Lars was an exceptional colleague and leader who cared deeply about Lundbeck, our people and the difference we make for patients. He made an important and lasting contribution to Lundbeck over almost four decades and will be deeply missed. Our thoughts are with his family and loved ones at this very difficult time," says Charl van Zyl, President & CEO of Lundbeck.

Lundbeck is putting interim leadership arrangements in place for Product Development & Supply while a permanent leadership solution is determined.

Contacts

Jens Høyer
Vice President, Head of Investor Relations
JSHR@lundbeck.com
+45 30 83 45 01

Anders Crillesen
Senior Director, External & Internal Relations
AECE@lundbeck.com
+45 27 79 12 86

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.